Retrograde nerve growth factor signaling abnormalities in familial dysautonomia

Lin Li, … , Katherine Gruner, Warren G. Tourtellotte


Find the latest version:
https://jci.me/130401/pdf
Retrograde nerve growth factor signaling abnormalities in familial dysautonomia

Lin Li,1 Katherine Gruner,1 and Warren G. Tourtellotte1,2,3,4

Familial dysautonomia (FD) is the most prevalent form of hereditary sensory and autonomic neuropathy (HSAN). In FD, a germline mutation in the Elp1 gene leads to Elp1 protein decrease that causes sympathetic neuron death and sympathetic nervous system dysfunction (dysautonomia). Elp1 is best known as a scaffolding protein within the nuclear hetero-hexameric transcriptional Elongator protein complex, but how it functions in sympathetic neuron survival is very poorly understood. Here, we identified a cytoplasmic function for Elp1 in sympathetic neurons that was essential for retrograde nerve growth factor (NGF) signaling and neuron target tissue innervation and survival. Elp1 was found to bind to internalized TrkA receptors in an NGF-dependent manner, where it was essential for maintaining TrkA receptor phosphorylation (activation) by regulating PTPN6 (Shp1) phosphatase activity within the signaling complex. In the absence of Elp1, Shp1 was hyperactivated, leading to premature TrkA receptor dephosphorylation, which resulted in retrograde signaling failure and neuron death. Inhibiting Shp1 phosphatase activity in the absence of Elp1 rescued NGF-dependent retrograde signaling, and in an animal model of FD it rescued abnormal sympathetic target tissue innervation. These results suggest that regulation of retrograde NGF signaling in sympathetic neurons by Elp1 may explain sympathetic neuron loss and physiologic dysautonomia in patients with FD.

Introduction
Humans with FD have debilitating sympathetic nervous system dysfunction (dysautonomia) that impairs normal cardiovascular, renal, gastrointestinal, and pulmonary function, and most patients afflicted by the disease have a shortened lifespan despite aggressive symptomatic treatment (1, 2). FD is caused by a homozygous splice-site mutation in the Elp1 gene (also known as IKKKAP), which leads to nonsense-mediated mRNA degradation and reduced Elp1 protein (3, 4). Elp1 was identified as a noncatalytic scaffolding protein within the heterohexameric transcriptional Elongator complex (5) and therefore, abnormalities in gene transcription have been thought to be central to the pathogenesis of dysautonomia in FD (6–8). However, most Elp1 protein is localized in the cytoplasm of cells, suggesting that it may also have a function apart from transcription. Previous studies have shown that Elp1, as part of the Elongator complex, may have a role in alpha-tubulin acetylation to regulate cortical neuron migration and differentiation (9, 10). In addition, many studies have shown that Elongator has a role in mRNA translation by modifying tRNA wobble uridines involved in codon bias and translational efficiency (11–16), but whether alterations in transcription or translation of select genes and proteins in sympathetic neurons explains their death in FD is not known. Previous studies have shown that Elp1-deficient sympathetic neurons can survive normally in vitro when immersed in media containing their obligate survival factor, nerve growth factor (NGF) (17), suggesting that broad abnormalities in gene transcription or translation may not adequately explain sympathetic neuron death in patients with FD.

During their development, sympathetic neurons acquire NGF from target tissues, which is required for their survival and target tissue innervation. NGF binds to TrkA (NTRK1) receptors on axon terminals, causing receptor homodimerization and autophosphorylation of specific endodomain tyrosine residues, which serve as docking sites for essential signal transduction mediators. The ligand bound and phosphorylated receptors are internalized and incorporated into NGF/TrkA signaling endosomes that are retrogradely transported to the neuron cell body to engage signal transduction pathways required for target tissue innervation and sympathetic neuron survival (18–20). Sympathetic and some sensory neurons that depend on NGF signaling for survival are particularly affected in FD, raising the possibility that NGF signaling abnormalities may have a role in disease pathogenesis (21, 22). Moreover, patients afflicted by other rare forms of HSAN have sympathetic and sensory nervous system abnormalities caused by gene mutations known to affect NGF signaling. For example, HSAN5 (OMIM 608654) and HSAN4 (OMIM 256800) are caused by rare germline mutations in the NGF and TrkA genes, respectively. Here, we identified an unexpected and essential role for cytoplasmic Elp1 in retrograde NGF signaling that may elucidate the mechanism by which sympathetic neurons die in patients with FD.

Results
Elp1 is ubiquitously expressed in all cells and ablating it in the germline in mice leads to early embryonic lethality (23). Humans with FD have a germline mutation in the Elp1 gene with a phenotype largely restricted to sympathetic and some sensory neurons.
in the Elp1 gene with loxP sites in the mouse germline (Elp1 +/f20) generated mice to recapitulate the FD mutation by flanking exon 20 in these neurons relative to other cells (24). Leading to exon 20 skipping and protein loss that is more severe This is because the mutation causes Elp1 splicing abnormalities, leading to exon 20 skipping and protein loss that is more severe in these neurons relative to other cells (24). We previously generated mice to recapitulate the FD mutation by flanking exon 20 in the Elp1 gene with loxP sites in the mouse germline (Elp1+/f20) mice (17). To explore the mechanism of Elp1 function in sympathetic neurons, Elp1+/f20 mice were mated to tamoxifen-dependent cre-recombinase–expressing mice (Rosa26CreERT2 mice) so that normal sympathetic neurons (Tcctl and TEIpl+/f20/f20 mice) were identified when NGF was present in both CB and DA compartments (28), similar to previous results with dissociated Elp1-deficient sympathetic neurons immersed in NGF-containing medium and where dependence on retrograde NGF signaling is bypassed (17). Here, we found that significant retrograde survival differences were identified between Tcctl and TcKO neurons even when the NGF concentration was elevated 50-fold (from 10 ng/mL to 500 ng/mL) in the DA compartment. Since NGF is produced in limiting quantities by peripheral tissues in vivo, these results suggest that impaired retrograde NGF signaling in TcKO neurons could underly sympathetic neuron survival and target tissue innervation abnormalities in patients with FD (Figure 1B).

Elp1 may have a role in transcriptional regulation in the nucleus as a constituent of the transcriptional Elongator protein complex (9). However, in sympathetic neurons almost all detectable Elp1 protein is localized outside of the nucleus (Supplemental Figure 2A) and in a distinctly punctate pattern in the cytoplasm and in axons (Supplemental Figure 2B), that we previously identified as Rab7-positive late endosomes thought to, at least in part, also represent NGF-signaling endosomes (28, 29). Moreover, consistent with the concept that at least some Elp1-containing endosomes may also represent NGF-signaling endosomes, there was a significant increase in Elp1-positive endosomes in proximal axons 5 hours after NGF treatment of DAs (Supplemental Figure 2C). To examine whether cytoplasmic Elp1 has a function to cultured neurons (TcKO) under various experimental conditions and at different stages during NGF-dependent differentiation in vitro (Supplemental Figure 1C). Dissociated TcKO sympathetic neurons lacking Elp1 survived normally when completely immersed in NGF-containing culture medium, as previously reported by us for neurons derived from Elp1-sympathetic neuron-specific (conditional) knockout mice (17) and similar to wild type sympathetic neurons (25).

Immersing dissociated sympathetic neurons in NGF-containing medium bypasses their need to transport NGF from distal axons (DAs) for survival and it does not reflect the way NGF is normally acquired by axons as they innervate target tissues during development in vivo. To more closely emulate these conditions and to interrogate retrograde NGF signaling in Elp1-deficient neurons, we established partitioned cultures (26), which have been extensively used to define the mechanisms of retrograde NGF/TrkA signaling in sympathetic neurons (reviewed in ref. 27). Tcctl and TcKO neurons were grown in partitioned culture, bisbenzimide (Bis) staining was used to distinguish live from dead neurons, and fluorescent microspheres (FS) were added to the DA compartment medium to identify retrogradely labeled neurons that extended axons into the DA compartment (Figure 1A). In previous studies, we identified a highly significant retrograde survival abnormality of TcKO neurons relative to Tcctl neurons when NGF was restricted to the DA compartment. By contrast, no survival differences between Tcctl and TcKO neurons were identified when NGF was present in both CB and DA compartments (28), similar to previous results with dissociated Elp1-deficient sympathetic neurons immersed in NGF-containing medium and where dependence on retrograde NGF signaling is bypassed (17). Here, we found that significant retrograde survival differences were identified between Tcctl and TcKO neurons even when the NGF concentration was elevated 50-fold (from 10 ng/mL to 500 ng/mL) in the DA compartment. Since NGF is produced in limiting quantities by peripheral tissues in vivo, these results suggest that impaired retrograde NGF signaling in TcKO neurons could underly sympathetic neuron survival and target tissue innervation abnormalities in patients with FD (Figure 1B).
in retrograde NGF-dependent survival signaling in sympathetic neurons, we generated doxycycline-inducible adenoviruses to reconstitute either nuclear-localized (Elp1-nuc) or cytoplasm-localized (Elp1-cyto) forms of Elp1 in sympathetic neurons lacking endogenous Elp1 protein (Supplemental Figure 3). Titrating the concentration of doxycycline in the culture medium made it possible to reexpress the exogenous molecules at near physiologic levels (Supplemental Figure 4). GFP+/FS+ TcKO neurons infected with virus expressing only GFP showed retrograde survival abnormalities relative to GFP+/FS+ TCtl neurons, as we previously reported for TcKO sympathetic neurons (ref. 28 and Figure 1C). However, in GFP+/FS+ TcKO neurons that reexpressed GFP and WT Elp1, retrograde neuron survival was completely rescued, as expected. Reexpression of Elp1-nuc in TCtl sympathetic neurons showed no significant rescue of retrograde survival in GFP+/FS+ neurons, whereas reexpression of Elp1-cyto completely rescued retrograde survival signaling (Figure 1C). Thus, normal NGF-dependent retrograde survival of sympathetic neurons requires Elp1 function in the cytoplasm.

Retrograde NGF signaling in sympathetic neurons is a complex process. Elp1 could be involved in many aspects of NGF/TrkA signaling, including TrkA expression on the surface of axons, internalization of the NGF/TrkA receptor complex, phosphorylation (activation) of the TrkA receptor, and incorporation of the NGF/TrkA complex into signaling endosomes and/or their retrograde transport to the cell body to engage downstream signaling pathways. Cell-surface biotinylation of bulk-cultured sympathetic neurons showed normal cell-surface TrkA expression in TCtl compared with TcKO neurons (Supplemental Figure 5). Moreover, consistent with our previous results showing that Elp1-deficient sympathetic neurons survive normally when immersed in NGF-containing medium (17), we observed normal cell-surface TrkA receptor internalization and phosphorylation at Y490 of the receptor endodomain in bulk-cultured neurons treated with NGF (Figure 2A). To better recapitulate in vivo retrograde NGF signaling mechanisms, compartmentalized cultures and axon surface protein biotinylation in the DA compartment were used to examine NGF-dependent TrkA receptor internalization, activation, and trafficking from DAs to neuron cell bodies. Twenty minutes after NGF treatment in the DA compartment, both TCtl and TcKO axons internalized cell-surface TrkA receptors. The internalized receptors were similarly phosphorylated at Y490 (Figure 2B) and Y674/5 (Supplemental Figure 6A). By 5 hours after NGF treatment and DA cell-surface biotinylation, internalization and retrograde transport of biotinylated TrkA receptors to the cell body (green arrowhead) was similar between TCtl and TcKO neurons (Student’s t test; NS, n = 0.38, n = 3–6). Similarly, DA cell-surface biotinylation in partitioned neuron cultures showed that TCtl and TcKO neurons were similar in their ability to internalize cell-surface TrkA receptors (Student’s t test; NS, n = 0.25, n = 3–6). Five hours after NGF treatment and DA cell-surface biotinylation, internalization and retrograde transport of biotinylated TrkA receptors to the cell body (green arrowhead) was similar between TCtl and TcKO neurons (Student’s t test; NS, n = 0.92, n = 3). However, the retrogradely transported TrkA axon-surface receptors were not phosphorylated in TcKO neurons compared with TCtl neurons (Student’s t test; *P < 0.00002, n = 11).

Figure 2. Abnormal retrograde TrkA receptor phosphorylation (activation) in the absence of Elp1. (A) TCtl and TcKO neurons grown in bulk culture and differentiated for 5–7 days were deprived of NGF for 24 hours using NGF-free medium, anti-NGF antibody (0.05 μg/mL), and BAF (50 μM) to prevent neuronal apoptosis. Cell-surface proteins were biotinylated at 4°C and the neurons were either left unchallenged or they were challenged with NGF (10 ng/mL) for 20 minutes at 37°C. Excess cell-surface biotin was stripped from the live neurons and total cellular and membrane protein lysates were obtained. Internalized biotinylated proteins were isolated by streptavidin affinity purification (AP) and the proteins were subjected to Western blotting and film densitometry. There was no detectable abnormality in TrkA receptor internalization in response to NGF in TcKO neurons (Student’s t test; P = 0.89, n = 7–9), and internalized TrkA receptors showed no difference in phosphorylation at Y490 20 minutes after NGF treatment (Student’s t test; P = 0.38, n = 3–6). (B) Similarly, DA cell-surface biotinylation in partitioned neuron cultures showed that TCtl and TcKO neurons were similar in their ability to internalize cell-surface TrkA receptors (Student’s t test; NS, n = 0.19, n = 3) and phosphorylate the receptors at Y490 within axons (green arrowhead) 20 minutes after NGF treatment (Student’s t test; NS, n = 0.92, n = 3). (C) Five hours after NGF treatment and DA cell-surface biotinylation, internalization and retrograde transport of biotinylated TrkA receptors to the cell body (green arrowhead) was similar between TCtl and TcKO neurons (Student’s t test; NS, n = 0.25, n = 3). However, the retrogradely transported TrkA axon-surface receptors were not phosphorylated in TcKO neurons compared with TCtl neurons (Student’s t test; *P < 0.00002, n = 11).
surface expression of TrkA receptors, their NGF-dependent internalization, their initial phosphorylation/activation at critical tyrosine residues in axons, or retrograde transport of the receptors to the neuron cell body, it is essential for maintaining TrkA receptor phosphorylation/activation during retrograde transport.

NGF-induced phosphorylation of the TrkA endodomain at Y490 creates a well-characterized phosphotyrosine docking site.

Although axon surface TrkA receptor trafficking to the cell body was similar between TCtl and TcKO neurons, NGF-dependent TrkA phosphorylation at both Y490 (Figure 2C) and Y674/5 (Supplemental Figure 6B) was completely absent compared with TCtl neurons, which maintained TrkA receptor phosphorylation to the cell bodies for at least 5 hours after NGF treatment of DAs. Thus, while Elp1 has no appreciable role in sympathetic neuron cell.

Figure 3. Impaired retrograde TrkA receptor activation in Elp1-deficient neurons is associated with impaired activation of effector signaling pathways required for their differentiation and survival. TcKO sympathetic neurons failed to maintain retrograde TrkA receptor phosphorylation after NGF treatment of DAs, which was associated with failure to engage several well-established signaling pathways that are activated by retrograde TrkA signaling. For example, whereas Erk1/2, AKT, Erk5 and CREB were all phosphorylated in neuron cell bodies (green arrowhead) 5 hours after NGF treatment of DAs in TCtl neurons, significant abnormalities in their phosphorylation were observed in TcKO neurons after similar treatment (blot images and quantitative results are from multiple different experiments using an identical experiment protocol; Student’s t test; pErk 1/2, *P < 0.001, n = 6; pAKT, **P < 0.00002, n = 6; pErk5, ***P < 0.01, n = 5–6; pCREB, ****P < 0.003, n = 5).

Figure 4. Elp1 binds to the NGF/TrkA signaling complex and is associated with NGF signaling endosomes. (A) Consecutive cell-surface biotinylation, affinity purification of internalized biotinylated proteins, and TrkA immunoprecipitation from TCtl sympathetic neurons showed that Elp1 was bound to the internalized NGF/TrkA signaling complex and that (B) cytosolic Elp1 was recruited to phosphorylated TrkA receptors after NGF treatment (results representative of n = 3 replicates). (C) In TCtl neurons, NGF treatment of DAs significantly increased the recruitment of Elp1 to TrkA-GFP labeled signaling endosomes (arrowhead) (Student’s t test; *P < 0.0001, n = 23–29). Scale bar: 2 μm.
sympathetic neuron death and abnormal target tissue innervation in patients with FD.

To examine how Elp1 maintains TrkA phosphorylation during retrograde NGF signaling, we first examined whether Elp1 was recruited to internalized TrkA receptors when sympathetic neurons were exposed to NGF. We found that Elp1 was recruited to internalized cell-surface biotinylated TrkA receptors (Figure 4A), and that recruitment was NGF dependent (Figure 4B). This was confirmed using another method in neurons expressing TrkA-GFP, in which Elp1 association with GFP-labeled TrkA signaling endosomes in proximal axons was increased when NGF was presented to DAs in partitioned cultures (Figure 4C).

Previous studies showed that Shp1 (PTPN6) phosphatase associates with TrkA in an NGF-dependent manner and it regulates TrkA signaling and sympathetic neuron survival by regulating TrkA phosphorylation (34). We confirmed NGF-dependent Shp1 recruitment to the TrkA signaling complex in sympathetic neurons, as previously reported that is essential to engage Ras-MAPK and Ras-PI3K signaling pathways, both of which are essential for sympathetic neuron survival and differentiation. Signaling endosomes containing NGF bound and activated TrkA receptors maintain prolonged activation of these pathways during their retrograde transport to the cell body. A failure to maintain TrkA phosphorylation would be expected to impair the activation of critical effector signaling pathways required for sympathetic neuron survival and differentiation (for review see ref. 30). Consistent with this hypothesis, we found that essential downstream effectors of retrograde TrkA receptor signaling, such as Erk1/2, AKT, Erk5, and CREB, were not retrogradely phosphorylated (activated) by NGF acquired from DAs in TcKO neurons lacking Elp1, like they were in TCtl neurons (Figure 3).

Figure 5. Elp1 maintains TrkA phosphorylation by negatively regulating Shp1 phosphatase activity. (A) Shp1 and Elp1 recruitment to a protein complex containing TrkA in TCtl neurons is NGF-dependent and binding of Shp1 to TrkA is independent of Elp1 (results representative of n = 3 replicates). (B) Although no detectable differences in total phosphatase activity were identified between TCtl and TcKO neurons, immunoprecipitation of Shp1 showed it was significantly hyperactivated in the absence of Elp1 in TcKO neurons compared with TCtl neurons (Student’s t test; *P < 0.00001, n = 4). (C) Adenovirus-mediated expression of a short hairpin RNA (shShp1) reduced the level of Shp1 protein more than 80% relative to expression of a scrambled (shScr) shRNA in TCtl neurons. (D) Whereas TcKO neurons expressing shScr showed significant retrograde NGF-dependent survival abnormalities (Student’s t test; *P < 0.001, n = 3–6), expression of shShp1 significantly and completely rescued retrograde NGF-dependent survival (Student’s t test; **P < 0.00001, n = 4). (E) Accordingly, the level of retrograde pTrkA in cell bodies was highly decreased in TcKO neurons compared with TCtl neurons infected with adenovirus expressing shScr (Student’s t test; *P < 0.000005, n = 28) and it was completely rescued by infection with shShp1-expressing adenovirus (Student’s t test; **P < 0.0001, n = 11; arrowheads, results represent pTrkA fluorescence). Scale bars: 25 μM. For D and E, the results were considered significant if the Bonferroni’s corrected P value was less than 0.017.
TrkA signaling by regulating Shp1 activity and TrkA phosphorylation in sympathetic neurons were grown in partitioned cultures with NGF in the DA compartment together with Shp1 phosphatase inhibitors. To test this hypothesis, TCtl and TcKO neurons may explain the impaired retrograde NGF/TrkA signaling in the absence of Elp1, which was clearly detectable under Shp1 protein-enrichment conditions using immunoprecipitation (Figure 5B). To determine whether Shp1 hyperactivity is responsible for the abnormal regulation of NGF/TrkA phosphorylation and decreased retrograde neuron survival in the absence of Elp1, previously characterized dominant-negative Shp1 (dnShp1) and small hairpin Shp1 RNA (shShp1) molecules were expressed to specifically abrogate Shp1 function (35). Adenovirus-mediated expression of dnShp1 in TcKO Elp1-deficient sympathetic neurons was able to significantly, but incompletely, rescue retrograde NGF-mediated sympathetic neuron survival (Supplemental Figure 8). The incomplete rescue of retrograde neuron survival by dnShp1 may be due to incomplete inhibition of Shp1. To test this hypothesis, expression of shShp1, which resulted in a more than 80% reduction in endogenous Shp1 protein (Figure 5C), completely rescued retrograde neuron survival (Figure 5D). As expected, retrograde pTrkA levels in the cell body were significantly elevated (Figure 5E). These results suggest that failure of retrograde NGF/TrkA signaling in the absence of Elp1 is a consequence of Shp1 hyperactivation, which leads to precocious TrkA dephosphorylation and impaired activation of downstream survival and differentiation signal transduction pathways.

Hyperactivation of Shp1 phosphatase in sympathetic neurons may explain the impaired retrograde NGF/TrkA signaling in Elp1-deficient neurons, suggesting that pharmacological inhibition of Shp1 might also be useful to rescue disease-relevant sympathetic neuron death. To test this hypothesis, TCtl and TcKO neurons were grown in partitioned cultures with NGF in the DA compartment together with Shp1 phosphatase inhibitors NSC87877 (NSC; Figure 6, A and B) or sodium stibogluconate (SSG; Supplemental Figure 9) in both compartments. Whereas in the absence of either inhibitor, retrograde TrkA phosphorylation at Y490 and Y674/5 was completely absent in TcKO neurons as previously shown, it was rescued by the presence of either Shp1 phosphatase inhibitor (Figure 6A and Supplemental Figure 9). Moreover, increased TrkA phosphorylation was accompanied by a small but significant increase in NGF-dependent survival in TCtl neurons as previously reported (34), and retrograde neuron survival was completely rescued in TcKO neurons by pharmacological Shp1 phosphatase inhibition (Figure 6B).

To examine whether Shp1 phosphatase inhibition can protect sympathetic neurons lacking Elp1 in vivo, pregnant mice were implanted with subcutaneous osmotic pumps to systemically deliver Shp1 phosphatase inhibitor NSC or PBS starting at embryonic day 11.5. Embryos received drug or PBS in utero, and after birth the neonatal mice continued to receive drug from lactating dams before they were examined at postnatal day 5. Neonatal mice with Elp1 loss specifically in sympathetic neurons (DβH-iCre+ Elp1f20/f20 [Elp1-cKO]) and control neonatal mice (PBS-treated Elp1-Ctl mice, (D) PBS-treated Elp1-cKO mice showed markedly diminished pTrkA in SCG sympathetic neurons (Student’s t test; **P < 0.000001, n = 18 images from 3 animals; image gain shown in D magnified 5 times to visualize low signal). (E) Treatment with NSC significantly rescued pTrkA in Elp1-cKO mice compared with PBS-treated Elp1-cKO mice (Student’s t test; ***P < 0.000001, n = 36 images from 3 animals). Scale bars in C–E, 50 μm. For B, the results were considered significant if the Bonferroni’s corrected P value was less than 0.012 and for C if it was less than 0.0017.

Figure 6. The phosphatase inhibitor NSC87877 rescues retrograde TrkA phosphorylation and neuron survival. (A) Pharmacologic inhibition of Shp1 using the phosphatase inhibitor NSC87877 (NSC) rescued retrograde TrkA Y490 and Y674/5 phosphorylation (pTrkA) in sympathetic neurons grown in partitioned cultures when challenged with NGF at their terminals (results representative of n = 3 replicates). (B) NSC slightly enhanced retrograde neuron survival of TCtl neurons as previously reported for Shp1 inhibition (34) (Student’s t test; *P < 0.001, n = 30–37 images from 3 experimental replicates) and it completely rescued retrograde NGF-dependent neuron survival in TcKO neurons (Student’s t test; **P < 0.000001, n = 3–37 images from 3 experimental replicates). pTrkA was also rescued in vivo by NSC treatment. Compared with (C) PBS-treated (-NSC) Elp1-Ctl mice, (D) PBS-treated Elp1-cKO mice showed markedly diminished pTrkA in SCG sympathetic neurons (Student’s t test; ***P < 0.000001, n = 18 images from 3 animals; image gain shown in D magnified 5 times to visualize low signal). (E) Treatment with NSC significantly rescued pTrkA in Elp1-cKO mice compared with PBS-treated Elp1-cKO mice (Student’s t test; ***P < 0.000001, n = 36 images from 3 animals). Scale bars in C–E, 50 μm. For B, the results were considered significant if the Bonferroni’s corrected P value was less than 0.012 and for C if it was less than 0.0017.
Discussion

A systematic and mechanistic analysis of disease-relevant sympathetic neurons isolated from mice with acutely ablated Elp1 has identified an NGF signaling abnormality that may explain sympathetic neuron death and sympathetic dysautonomia in patients with FD. After NGF binding to cell-surface TrkA receptors on sympathetic axons in target tissues, Elp1 protein is recruited to NGF-bound and -internalized receptors, which also recruit the TrkA regulatory Shp1 phosphatase. In WT sympathetic neurons, NGF/TrkA phosphorylation is maintained in signaling endosomes by Elp1-mediated negative regulation of Shp1 during retrograde transport to the cell body, and downstream signaling mediators required for survival and differentiation, such as Erk1/2, AKT, Erk5, and CREB, are phosphorylated and activated. In the absence of Elp1, however, Shp1 bound to the NGF/TrkA signaling complex becomes hyperactivated, leading to premature TrkA dephosphor-
deficient sensory and sympathetic neurons normally migrated from the neural crest. There was no identifiable abnormality in total neuron number, proliferation, or apoptosis in the primordial ganglia at a developmental time point before their innervation of target tissues and dependency on NGF signaling. Interestingly, we identified markedly elevated neuronal apoptosis in sympathetic and sensory ganglia at birth, when sensory and sympathetic neurons are actively innervating target tissues and they depend on target tissue–derived NGF signaling for survival (37). These results are consistent with the hypothesis proposed many decades ago suggesting that NGF signaling may have a role in sympathetic and sensory neuron loss in the pathogenesis of FD (21, 22).

Retrograde NGF transport abnormalities were previously identified in mice lacking Elp1 in DRG sensory neurons (38). These studies showed decreased acetylated alpha-tubulin and reduced velocity of retrogradely transported NGF from dis-

Figure 8. The Shp1 phosphatase inhibitor, NSC87877 (NSC) rescues sympathetic ganglion volume in a mouse model of FD. (A) Sympathetic ganglion (SCG arrowhead/green mask and stellate ganglion/green mask; STG arrow) volume was measured using tyrosine hydroxylase immunofluorescence, whole organ tissue clearing, light sheet confocal microscopy and 3D reconstruction with volumetric masking. (B) A significant decrease in ganglion volume was observed in PBS-treated Elp1-cKO (SCG, Student’s t test, *P = 0.001, n = 10; STG, Student’s t test, *P = 0.003, n = 10). Elp1-cKO mice treated with NSC showed a significant rescue in ganglionic volume (SCG, Student’s t test, NS, P = 0.166, n = 10; STG, Student’s t test, *P = 0.01, n = 11). Scale bar: 1 mm. The results were considered significant if the Bonferroni’s corrected P value was less than 0.017.
Elp1 interacts with the previously characterized NGF/TrkA/Shp1 signaling complex, was found to alter the modification of wobble nucleosides in 2 tRNA species that modulate the protein translation efficiency of a subset of transcripts in fission yeast (11, 16). There is now widespread consensus that this function is evolutionarily conserved in eukaryotes, where it may have a role in regulating the translation efficiency of a broad number of transcripts (12, 13, 41). Of particular relevance, a recent study reported widespread abnormalities in protein translation in Elp1-deficient sensory neurons that may have a role in TrkA-expressing nociceptive neuron survival in FD during development (14). Although the role of Elp1 in modulating protein translation efficiency seems clear, the extent to which this may explain neuron death in sensory neurons in FD is somewhat less clear from this study, considering the likelihood that maladaptive developmental regulatory mechanisms may have confounded the proteomic and expression analyses that were performed on E17.5 neurons, long after Elp1 was ablated in vivo by Wnt1-Cre at approximately E9.5 gestation (42). Nevertheless, it seems plausible that protein translation may be altered in sympathetic neurons lacking Elp1, but we did not identify differences between TCtl and TcKO neurons in the level of any of the specific proteins that we examined (TH, Tuj1, TrkA, Shp1, Erk 1/2, AKT, Erk5, or CREB) when normalized for total protein. Importantly, immunoprecipitated Shp1 protein complexes that contained similar amounts of Shp1 protein were tested in the phosphatase assays, which showed a clear increase in Shp1 phosphatase activity in TcKO neurons, eliminating the possibility that the result was due to altered Shp1 protein translation in TcKO neurons relative to TCtl neurons.

Elp1 interacts with the previously characterized NGF/TrkA/Shp1 signaling complex, but our results do not address whether the regulatory interaction is direct or indirect. Therefore, it is possible that loss of Elp1 may alter translational efficiency of other proteins that bind within the complex or outside of the complex to regulate Shp1 phosphatase activity. Indeed, Elp1 has previously been shown to primarily localize to intracellular endosomes (43) and in particular Rab7-positive endosomes (28). Rab7-positive endosomes are known to represent, at least in part, TrkA signaling endosomes (29, 44) and they are platforms for local protein translation in axons (45), raising the possibility that protein translation may be modulated by Elp1 within them. It is interesting that TrkA colocalizes with only about 50% of the Elp1-positive endosomes in proximal axons after NGF treatment of DAs, suggesting that Elp1 has a broader role in endosomal function in sympathetic neurons beyond its role in regulating TrkA signaling.

Elp1 interacts with the NGF/TrkA/Shp1 signaling complex to regulate Shp1 activity, but whether it has a similar function in NGF-dependent nociceptive sensory neurons that also degenerate in FD is currently unknown. Shp1 contains 2 Src homology 2 (SH2) protein-protein interaction domains that regulate its phosphatase activity through coordinated interaction with binding partner proteins. Elp1 may have a role in coordinating these protein interactions to regulate its function, but the specific binding partner proteins and interaction domains have not yet been characterized. Elp1 appears to have an essential function in regulating Shp1 phosphatase activity during retrograde NGF signaling, and it may regulate other proteins in sympathetic neurons and in other cells. Early embryonic lethality in mice lacking Elp1 in all cells clearly shows it has a widespread function beyond its role in regulating TrkA receptor signaling in sympathetic neurons. Shp1 is broadly expressed and has a role in regulating many tyrosine kinase receptors, and it appears to be a tumor suppressor gene in lymphoma, leukemia, and a variety of solid tumors (46). Whether Elp1 has a role in regulating Shp1 phosphatase activity to modulate tyrosine kinase receptor signaling in other cell types and their growth, differentiation, and oncogenic potential will be interesting to explore in future studies.

Methods

Methods, including statements of reagent availability and references, are available in the Supplemental Methods.

Study approval. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Cedars Sinai Medical Center in Los Angeles California (approval IACUC007292).

Author contributions

WGT conceived the project and designed the studies. LL, KG, and WGT performed experiments. WGT and LL analyzed the data, and WGT wrote the manuscript.

Acknowledgments

We thank T. Fu and C. Re Bogguri for providing technical assistance. R. Kuruvilla, D. Ginty, and J. Levitt provided recombinant adenovirus vectors. This work was supported by NIH grants R21-HD064918, K26-OD010945, R56-NS089626, and R01-NS095894.

Address correspondence to: Warren G. Tourtellotte, Department of Pathology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 8719, Los Angeles, California 90048, USA. Phone: 310.248.7736; Email: warren.tourtellotte@cshs.org.


